$530,000 of EMERGENT BIOSOLUTIONS INC lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"- Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY26 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY26 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 - Tribal Opioid Response Grant funding for FY26 - NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone - H.R.1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 - H.R.2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 - H.R.5252, Having Overdoes Protection Equipment Act - Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY26 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY26 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 - Tribal Opioid Response Grant funding for FY26 - NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone - H.R.1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 - H.R.2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 - H.R.5252, Having Overdoes Protection Equipment Act - Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY26 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY26 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 - Tribal Opioid Response Grant funding for FY26 - NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone - H.R.1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 - H.R.2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 - H.R.5252, Having Overdoes Protection Equipment Act - Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY26 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY26 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 - Tribal Opioid Response Grant funding for FY26 - NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone - H.R.1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 - H.R.2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 - H.R.5252, Having Overdoes Protection Equipment Act"
You can find more data on corporate lobbying on Quiver Quantitative.
EBS Insider Trading Activity
EBS insiders have traded $EBS stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $EBS stock by insiders over the last 6 months:
- DONALD W DEGOLYER sold 7,844 shares for an estimated $67,830
- KATHRYN C ZOON sold 7,086 shares for an estimated $62,852
- KEITH KATKIN sold 7,844 shares for an estimated $49,417
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
EBS Hedge Fund Activity
We have seen 94 institutional investors add shares of EBS stock to their portfolio, and 79 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 2,525,313 shares (+137.6%) to their portfolio in Q2 2025, for an estimated $16,111,496
- OAK HILL ADVISORS LP added 2,500,000 shares (+224.5%) to their portfolio in Q2 2025, for an estimated $15,950,000
- MILLENNIUM MANAGEMENT LLC removed 1,747,056 shares (-69.8%) from their portfolio in Q2 2025, for an estimated $11,146,217
- QUBE RESEARCH & TECHNOLOGIES LTD removed 740,415 shares (-68.1%) from their portfolio in Q2 2025, for an estimated $4,723,847
- GEODE CAPITAL MANAGEMENT, LLC added 666,708 shares (+108.9%) to their portfolio in Q2 2025, for an estimated $4,253,597
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 605,576 shares (-71.3%) from their portfolio in Q2 2025, for an estimated $3,863,574
- PACER ADVISORS, INC. added 556,730 shares (+inf%) to their portfolio in Q2 2025, for an estimated $3,551,937
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
EBS Analyst Ratings
Wall Street analysts have issued reports on $EBS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 09/03/2025
To track analyst ratings and price targets for EBS, check out Quiver Quantitative's $EBS forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
